BPTSY (Biophytis) ROE % Adjusted to Book Value: 0.00% (As of Jun. 2025)


BPTSY Biophytis SA BPTSY
18 GF Score
Price $0.25
! 5 Warning Signs
View Full Analysis

What is Biophytis ROE % Adjusted to Book Value?

Biophytis BPTSY 18 ROE % Adjusted to Book Value is 0.00% as of Jun. 2025. GuruFocus rates BPTSY with a GF Score™ of 18/100. The stock has 5 warning signs investors should review.

Biophytis's ROE % for the quarter that ended in Jun. 2025 was 0.00%. Biophytis's PB Ratio for the quarter that ended in Jun. 2025 was N/A. Biophytis's ROE % Adjusted to Book Value for the quarter that ended in Jun. 2025 was N/A.

Biophytis ROE % Adjusted to Book Value Related Terms

Biophytis ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Biophytis's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biophytis ROE % Adjusted to Book Value Chart

Biophytis Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 -68.06 0.00 0.00 0.00

Biophytis Semi-Annual Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

BPTSY vs VRTX, REGN, ALNY: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, Biophytis's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biophytis ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biophytis's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Biophytis's ROE % Adjusted to Book Value falls into.


BPTSY
18GF Score
Biophytis SA BPTSY
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biophytis ROE % Adjusted to Book Value Calculation

Biophytis's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / N/A
=N/A

Biophytis's ROE % Adjusted to Book Value for the quarter that ended in Jun. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / N/A
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of 0.00% mean?
Biophytis (BPTSY) has a ROE % Adjusted to Book Value of 0.00% as of Jun. 2025. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Biophytis and its competitors.
Is Biophytis' ROE % Adjusted to Book Value too high?
Biophytis' current ROE % Adjusted to Book Value is 0.00%. Overall, Biophytis has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Biophytis' ROE % Adjusted to Book Value compare to VRTX and REGN?
Biophytis' ROE % Adjusted to Book Value of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Biophytis and its competitors. Biophytis's current ROE % Adjusted to Book Value is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biophytis stock overvalued right now?
Biophytis (BPTSY) has a current ROE % Adjusted to Book Value of 0.00%. The current ROE % Adjusted to Book Value is 0.00%. Biophytis' overall GF Score™ is 18/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Biophytis (BPTSY), the current ROE % Adjusted to Book Value is 0.00% as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Biophytis Business Description

Address BC 9, Batiment A 4eme etage, 4 Place Jussieu, Sorbonne University, Paris, FRA, 75005
Biophytis SA is a France-based clinical-stage biotechnology company engaged in the development of drug candidates for the treatment of age-related and respiratory diseases. The company focuses on therapies that target degenerative processes associated with aging and improve functional outcomes. Its drug candidate, BIO101, is an orally administered small molecule under development for neuromuscular and respiratory indications, including sarcopenia, Duchenne muscular dystrophy (DMD), and respiratory failure.
18GF Score

Get the complete analysis for BPTSY

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.25
Price